Oslo, Norway, March 8, 2022 - Nykode Therapeutics AS (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced that
preclinical data from its Vaccibody vaccine platform technology will be
presented at the upcoming 2022 American Association for Cancer Research (AACR)
Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. 

Details of the poster presentation are as follows:

Abstract #: 3558
Title: A novel and versatile cytokine empowered DNA vaccine platform with
superior immune activating potential 
Authors: Beraas, et al. 
Session Title: Vaccines: Oncolytic and Prophylactic 
Session Date and Time: Tuesday, April 12, 2022 | 1:30 p.m. - 5:00 p.m. ET

The abstract is available in the Scientific Papers and Presentations section of
the Company's website. The e-poster will be available on the Company's website
on Friday, April 8, 2022.


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer